Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In this issue

In this issue Biotechnology Biotechnol. J. 2008, 3, 1460 Journal Ethical criteria for deep brain stimulation Synofzik and Schlaepfer, Biotechnol. J. 2008, 3, 1511–1520 Within the recent development of brain-machine-interfaces, deep brain stimulation (DBS) has become one of the most promising approaches for neuromodulation. After its introduc- tion more than 20 years ago, it has in clinical routine become a successful tool for treating neurological disorders like Parkinson’s disease, essential tremor and dystonia. Recent evi- dence also demonstrates efficacy in improving emotional and cognitive processing in ob- sessive-compulsive disorder and major depression, thus allowing new treatment options for refractory psychiatric diseases, and even indicating future potential to enhance function- ing in healthy subjects. This ethical analysis of empirical evidence from applying DBS to movement disorders and psychiatric disease reveals that wide-spread use of DBS for psy- chiatric indications is currently not legitimated and that the basis for enhancement purpos- es is even more questionable. Nevertheless, both applications might serve as ethically © Photodisc legitimate and promising purposes in the future. ............................................................ 1511 http://dx.doi.org/10.1002/biot.200800187 Neural stem cells Lederer and Santama, Biotechnol. J. 2008, 3, 1521 –1538 Recently, intense interest in the potential use of neural stem cells (NSC) in the clinical therapy of brain disease and injury has resulted in rapid progress in research on NSC and the induced reprogramming of differentiated somatic cells to revert to a pluripotent NSC-like state. In this review the authors provide state-of-the art knowledge on the NSC lineage, emphasizing on ground-breaking efforts of cellular reprogram- ming with the view to generating patient-specific stem cells for cell re- placement therapy. This is set against a summary of current practical procedures for the isolation, research and application of NSC. Both provide the backdrop for the translation of recent findings into innova- tive clinical applications in NSC-based regenerative medicine, with the hope of increasing the safety, efficiency and ethical acceptability of NSC-based therapies in the near future. ........................................... 1521 http://dx.doi.org/10.1002/biot.200800193 Gene therapy for CNS disorders Terzi and Zachariou, Biotechnol. J. 2008, 3, 1555 –1563 Over the last few years, a large number of preclinical and clinical studies have demonstrated the potential of gene therapy applications using adeno- associated viral (AAV) vectors. Gene transfer via AAV vectors has been par- ticularly successful for the treatment or adjunct therapy of several central nervous system (CNS) disorders. The present review summarizes the progress on AAV gene delivery models for three different CNS disorders. It discusses advances in AAV-mediated gene transfer strategies in animal models of Parkinson’s disease, Alzheimer’s disease and spinal cord trauma and the authors summarize the results from the first clinical studies using © US National Library of Medicine AAV systems. ............................................................................................. 1555 1460 © 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biotechnology Journal Wiley

In this issue

Biotechnology Journal , Volume 3 (12) – Dec 1, 2008

Loading next page...
 
/lp/wiley/in-this-issue-tgDDTXbmD6

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2008 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1860-6768
eISSN
1860-7314
DOI
10.1002/biot.200890107
Publisher site
See Article on Publisher Site

Abstract

Biotechnology Biotechnol. J. 2008, 3, 1460 Journal Ethical criteria for deep brain stimulation Synofzik and Schlaepfer, Biotechnol. J. 2008, 3, 1511–1520 Within the recent development of brain-machine-interfaces, deep brain stimulation (DBS) has become one of the most promising approaches for neuromodulation. After its introduc- tion more than 20 years ago, it has in clinical routine become a successful tool for treating neurological disorders like Parkinson’s disease, essential tremor and dystonia. Recent evi- dence also demonstrates efficacy in improving emotional and cognitive processing in ob- sessive-compulsive disorder and major depression, thus allowing new treatment options for refractory psychiatric diseases, and even indicating future potential to enhance function- ing in healthy subjects. This ethical analysis of empirical evidence from applying DBS to movement disorders and psychiatric disease reveals that wide-spread use of DBS for psy- chiatric indications is currently not legitimated and that the basis for enhancement purpos- es is even more questionable. Nevertheless, both applications might serve as ethically © Photodisc legitimate and promising purposes in the future. ............................................................ 1511 http://dx.doi.org/10.1002/biot.200800187 Neural stem cells Lederer and Santama, Biotechnol. J. 2008, 3, 1521 –1538 Recently, intense interest in the potential use of neural stem cells (NSC) in the clinical therapy of brain disease and injury has resulted in rapid progress in research on NSC and the induced reprogramming of differentiated somatic cells to revert to a pluripotent NSC-like state. In this review the authors provide state-of-the art knowledge on the NSC lineage, emphasizing on ground-breaking efforts of cellular reprogram- ming with the view to generating patient-specific stem cells for cell re- placement therapy. This is set against a summary of current practical procedures for the isolation, research and application of NSC. Both provide the backdrop for the translation of recent findings into innova- tive clinical applications in NSC-based regenerative medicine, with the hope of increasing the safety, efficiency and ethical acceptability of NSC-based therapies in the near future. ........................................... 1521 http://dx.doi.org/10.1002/biot.200800193 Gene therapy for CNS disorders Terzi and Zachariou, Biotechnol. J. 2008, 3, 1555 –1563 Over the last few years, a large number of preclinical and clinical studies have demonstrated the potential of gene therapy applications using adeno- associated viral (AAV) vectors. Gene transfer via AAV vectors has been par- ticularly successful for the treatment or adjunct therapy of several central nervous system (CNS) disorders. The present review summarizes the progress on AAV gene delivery models for three different CNS disorders. It discusses advances in AAV-mediated gene transfer strategies in animal models of Parkinson’s disease, Alzheimer’s disease and spinal cord trauma and the authors summarize the results from the first clinical studies using © US National Library of Medicine AAV systems. ............................................................................................. 1555 1460 © 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Journal

Biotechnology JournalWiley

Published: Dec 1, 2008

There are no references for this article.